Britannia Pharmaceuticals Limited

Ipsen Pharma S.a.s.

Ethypharm, Inc.

Laurent Bertocchi

Jeremiah Harnett

Nathalie Mondoly

Marie-Madeleine Baronnet

Joel Richard

Michael J Dey

Pierre Tchoreloff

Joël Richard

Guillaume Benoist

Béatrice Hacher

Bernard Leclerc

Didier Nourrisson

Faïza Laredj

Beatrice Hacher

Faiza Laredj

A pharmaceutical composition contains apomorphine as the active pharmaceutical ingredient, a water-miscible co-solvent, an antioxidant, and water. The solution has a pH greater than 4. The pharmaceutical composition is suitable for parenteral administration for the treatment of Parkinson's disease. The process for the manufacture of the pharmaceutical composition includes weighing the apomorphine and introducing it into a container with the co-solvent and the antioxidant under agitation until complete dissolution takes place.

Therapeutical composition containing apomorphine as active ingredient

The present invention relates to a sustained-release drug composition consisting essentially of microparticles of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection formulation comprising the sustained-release drug composition suspended in an injection medium.

Sustained-release composition containing peptides as active ingredient

The invention relates to low-dose tablets obtained by directly compressing microgranules essentially constituted of a neutral support covered by a polymeric layer containing at least one pharmaceutically acceptable polymer and permitting the modified release of active substances in an aqueous medium, to which an active layer containing at least one active substance is applied. The inventive tablets advantageously exhibit a matrix effect similar to that obtained with conventional matrix tablets that depends on the nature of the polymer(s) used for the constitution of the polymeric layer. This matrix effect makes it possible to modify the release profile of the transported active substance based on the type of the polymer used. These tablets are particularly suited for realizing low-dose tablets. The invention also relates to a method for producing these tablets and to the use thereof, particularly for administering active substances in low to very low doses.

Low-dose tablets having a network of polymers

Growing community of inventors

Sylvains les Moulins, France

Laurent Bertocchi